- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03949634
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD):an Dynamic Randomized, Positive Control, Open, Multicenter Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will receive one of two treatment regimens:
Group A: intravenous infusion of pegylated liposomal doxorubicin(PLD) 35 mg/m2, d1; cyclophosphamide 600 mg/m2, intravenous infusion, d1; once every 21days, for 4 cycles. Sequential docetaxel 100 mg/m2, intravenous infusion, d1, or paclitaxel 80mg/m2,intravenous infusion, d1,8,15, once every 21 days, for 4 cycles.
Group B: intravenous infusion of doxorubicin 60 mg/m2, d1; cyclophosphamide 600 mg/m2, intravenous infusion, d1; sequential docetaxel 100 mg/m2, intravenous infusion, d1, or paclitaxel 80mg/m2,intravenous infusion, d1,8,15, once every 21days, for 4 cycles. The primary endpoint is cardiotoxity,the secondary endpoint is 5-year disease-free survival (DFS), 5-year overall survival (OS), and safety: hematology and non hematological toxicity.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Fudan University Affiliated Cancer Hospital
-
Contact:
- lichen tang, doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1.Subjects had histopathologically confirmed early stage breast cancer with adjuvant chemotherapy treatment evidence;
- 2.Age :18-75years old female;
- 3.High risk of recurrence: axillary lymph node-positive, or axillary lymph node negative with at least one of the following risk factors: triple negative breast cancer, histological grade III, the maximum tumor diameter> 5cm, Ki 67 ≥ 50%, vascular thrombosis positive;
- 4.ECOG score 0-1;
- 5.Expected survival time ≥ 12 months;
- 6.LVEF ≥ 55%;
- 7.Normal ECG, ST segment depression in patients such as coronary angiography, confirm <50% stenosis or incidental premature beats are acceptable;
- 8.Bone Marrow Function: ANC:≥1.5×109/L; PLT:≥100×109/L;Hb: ≥90g/L;
- 9.Liver and renal function:Serum creatinine ≤ normal upper limit (ULN) 1.5times; aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ULN 2.5times; total bilirubin (TBil) level:≤ ULN 1.5 times, or ≤ ULN 2.5times if Gilbert's syndrome are present;
- 10.Subjects are well-behaved, able to undergo treatment and follow-up, and voluntarily comply with this study and understood the study's research process and signed the informed consent.
Exclusion Criteria:
- 1.New York Heart Association (NYHA) Class II or greater heart failure;
- 2.Severe heart disease or discomfort, including but not limited to: High-risk uncontrolled arrhythmias, atrial tachycardia (heart rate>100/min at rest), significant ventricular arrhythmias (ventricular arrhythmias) or higher, atrioventricular block ([Mobitz 2] or third-degree atrioventricular block); Angina pectoris that needs to be treated with anti-anginal medicine; Valvular heart disease with clinical significance; Electrocardiogram shows transmural myocardial infarction; Uncontrolled high blood pressure(eg: Systolic blood pressure> 180 mmHg or diastolic blood pressure> 100 mmHg);
- 3.Prior received neoadjuvant chemotherapy;
- 4.Severe systemic infection or other serious disease;
- 5.Allergies to chemotherapeutic drugs or their excipients or intolerant patients;
- 6.Other malignant tumors have been found in the past 5 years,except for cured cervical carcinoma in situ, non melanoma of the skin;
- 7.Childbearing age patients who are pregnant or lactation and refusing to take effective contraceptive measures during the trial;
- 8.Received any other test drug treatment or participated in other clinical trials at the same time;
- 9.Other conditions considered to be inappropriate to be enrolled by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PLD plus CTX sequential docetaxel or PTX
pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide(CTX) 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel(PTX) 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
|
pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Other Names:
cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
Other Names:
docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
Other Names:
paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
Other Names:
|
Active Comparator: DOX plus CTX sequential docetaxel or PTX
doxorubicin(DOX) 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
|
cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
Other Names:
docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
Other Names:
paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
Other Names:
doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiotoxity
Time Frame: 2 years.
|
Congestive heart failure with clinical symptoms, or no symptoms but an abnormal LVEF
|
2 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
5-year DFS
Time Frame: 5 years
|
5-year disease-free survival rate
|
5 years
|
5-year OS
Time Frame: 5 years
|
5-year overall survival rate
|
5 years
|
Adverse events (AE)
Time Frame: 5 years
|
Incidence and Severity of adverse events according to the CTC AE V4.03
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: zhimin shao, doctor, Fudan University Affiliated Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Docetaxel
- Paclitaxel
- Doxorubicin
Other Study ID Numbers
- CSPC -DMS- BC-08
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Breast Cancer
-
AstraZenecaRecruitingBreast Cancer, Early Breast CancerUnited States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
-
Hoffmann-La RocheCompletedBreast Cancer, Early Breast CancerSerbia
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Hoffmann-La RocheCompletedEarly Breast CancerFrance, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
-
Consorzio OncotechActive, not recruiting
-
Hoffmann-La RocheCompleted
-
Novartis PharmaceuticalsTerminatedEarly Breast CancerSpain, Singapore, United States
Clinical Trials on PLD
-
InxMed (Shanghai) Co., Ltd.RecruitingPlatinum-resistant Ovarian CancerChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorUnited States
-
MorphotekCompletedEpithelial Ovarian CancerUnited States
-
Mayo ClinicRecruitingPolycystic Liver DiseaseUnited States
-
Fudan UniversityUnknownSoft Tissue SarcomaChina
-
Genentech, Inc.TerminatedOvarian CancerUnited States, Spain, Belgium, Canada, France, United Kingdom, Poland
-
ChimerixNo longer availableGliomaUnited States
-
AmgenTerminatedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerUnited States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
-
ChimerixActive, not recruitingEndometrial Cancer RecurrentUnited States
-
The First Affiliated Hospital of Guangzhou Medical...UnknownNon-small Cell Lung CancerChina